Biotherapies in cancer: towards improving clinical outcomes
Thursday 7 March 2019, 2.15pm - 7pm, The Francis Crick Institute, London
The new 'Medicine at the Crick' event series showcases major advances in biomedical science and raises awareness of the medical implications of major scientific advances. Interested members of the Crick and wider UK biomedical community are invited to attend. Each event comprises a series of short talks, one or two keynote lectures and a panel discussion. Members of the academic medical press and of the biomedical research community are also invited.
Our third Medicine at the Crick event, "Biotherapies in cancer: towards improving clinical outcomes", will be held on Thursday 7 March 2019, 2.15pm-7pm, at the Francis Crick Institute.
This event will review the profound opportunities of CAR-T cell therapy, adoptive cellular immunotherapies and checkpoint inhibitor therapy in the management of haematologic and metastatic solid tumours. These Immunotherapies, by leveraging the patient's immune system, are transforming clinical care, resulting in prolonged survival and even cancer cures in a previously palliative setting. The event will review recent breakthroughs in the field, challenges and opportunities in the translation of scientific findings into the clinic and the promise of leveraging adaptive cellular therapies to tackle cancer clonal evolution for patient benefit.
The event will be hosted by Professor Julian Downward, Dr Samra Turajlic and Professor Charles Swanton from the Crick and the keynote lecture will be given by Dr Martin Pule from the UCL Cancer Institute. Other speakers include Professor Adrian Hayday (Crick/King's College London), Professor Sergio Quezada (UCL Cancer Institute), Professor MD Inge Marie Svane (University of Copenhagen), Dr Dr Iraj Ali (Achilles Therapeutics), Dr Paolo Paoletti (GammaDelta Therapeutics) and Dr Christian Itin (Autolus Therapeutics).
Please register to order your free tickets for the event.